A Study Looking at How Insulin Icodec is Taken up in the Blood When Administered in Different Injection Sites in People With Type 2 Diabetes

Inclusion Criteria: * Male or female * Aged 18-69 years (both inclusive) at the time of signing informed consent * Body mass index between 18.5 and 38.0 kg/m\^2 (both inclusive) * Diagnosed with type 2 diabetes mellitus above or equal to 180 days prior to the day of screening * HbA1c (glycated haemoglobin) below or equal to 9.0 percentage at screening * Current daily basal insulin treatment of 0.2-1.0 (I)U/kg/day (both inclusive) with or without any of the following anti-diabetic drugs/regimens with stable doses above or equal to 90 days prior to the day of screening: * Any metformin formulation * Other oral antidiabetic drugs: DPP-4 inhibitors / SGLT2 inhibitors / Oral combination products (for the allowed individual oral antidiabetic drugs) * Oral or injectable GLP-1 (glucagon-like peptide 1) Receptor Agonists Exclusion Criteria: * Known or suspected hypersensitivity to trial product(s) or related products. * Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice).